

## Appendix

Table 1: The effect of Paxlovid on the risks of post-acute sequelae of COVID-19 and mortality from the disease

	Percentage of patients with the respective post-COVID sequelae		*Reduced risk of patients prescribed Paxlovid
	Control	Patients prescribed Paxlovid	
<b>Death</b>	13.5%	6.9%	38%
<b>Congestive heart failure</b>	2.4%	1.5%	30%
<b>Atrial fibrillation</b>	2.3%	1.4%	37%
<b>Coronary artery disease</b>	2.5%	1.7%	29%
<b>Chronic pulmonary disease</b>	1.7%	1.1%	32%
<b>Acute respiratory distress syndrome</b>	2.7%	1.3%	29%
<b>End-stage renal disease</b>	0.2%	0.1%	63%

\* Figures adjusted for study participants' demographics, clinical background and vaccination status.